titlesubtitle

freedepositcasino| Hehuang Pharmaceutical (00013.HK): Initiated a RAPHAEL registered phase 3 study in China to investigate HMPL-306 in the treatment of patients with relapsed/refractory acute myeloid leukemia with IDH1 and/or IDH2 mutations

editor|
44

Gelonghui May 14 丨 Hehuang Pharmaceutical (00013freedepositcasino.HK) today announced the launch of a HMPL-306 treatment in China for patients with isocitrate dehydrogenase ("IDH")1 or 2 mutationsfreedepositcasinoRelapsed/refractory acute myeloid leukemia (AML)freedepositcasinoRegistered Phase III clinical trial. The first subject received the first dose on May 11, 2024.

freedepositcasino| Hehuang Pharmaceutical (00013.HK): Initiated a RAPHAEL registered phase 3 study in China to investigate HMPL-306 in the treatment of patients with relapsed/refractory acute myeloid leukemia with IDH1 and/or IDH2 mutations